Cancer exosomes and NKG2D receptor-ligand interactions: Impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance

Seminars in Cancer Biology

Volumn 28, Issue 1, 2014, Pages 24-30

  Mincheva Nilsson, Lucia ^a   Baranov, Vladimir ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Cancer; Cytotoxicity; Exosomes; Immune suppression; MICA B; NK cells; NKG2D; RAET1; Tumour surveillance; ULBP

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NATURAL KILLER CELL RECEPTOR NKG2D; LIGAND; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CELL COMMUNICATION; CELL TRANSFORMATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EXOSOME; HUMAN; IMMUNOELECTRON MICROSCOPY; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TEMPERATURE STRESS; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGY; METABOLISM; NEOPLASM;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; EXOSOMES; HUMANS; IMMUNOLOGIC SURVEILLANCE; LIGANDS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K;

EID: 84926262086     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.02.010     Document Type: Review

References (66)

1. Denzer K., Kleijmeer M.J., Heijnen H.F.G., Stoorvogel W., Geuze H.J. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000, 113:3365-3374.
2. Thery C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002, 2:569-579.
3. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009, 9:581-593.
4. Matsua H., Chevallier J., Mayran N., Le Blanc I., Ferguson C., Fauré J., et al. Role of LBPA and Alix in multivesicular liposome formation and endosomal organization. Science 2004, 303:531-534.
5. Mignot G., Roux S., Thery C., Ségura E., Zitvogel L. Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med 2006, 10:376-388.
6. Clayton A., Mason M.D. Exosomes in tumor immunity. Curr Oncol 2009, 16:46-49.
7. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
8. Fader C.M., Savina A., Sanchez D., Colombo M.I. Exosome secretion and red cell maturation: exploring molecular components involved in the docking and fusion of multivesicular bodies in K562 cells. Blood Cells Mol Dis 2005, 35:153-157.
9. Raposo G., Nijman W., Stoorvogel W. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996, 183:1161-1172.
10. Heijnen H.F.G., Schiel A.E., Fijnheer R., Geuze H.J., Sixma J.J. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and a-granules. Blood 1999, 94:3037-3799.
11. Karlsson M., Lundin S., Dahlgren U., Kahu H., Pettersson I., Telemo E. Tolerosomes are produced by intestinal epithelial cells. Eur J Immunol 2001, 31:2892-2900.
12. Mincheva-Nilsson L., Nagaeva O., Sundqvist K.G., Hammarström M.L., Hammarström S., Baranov V. γδT cells of human early pregnancy decidua: evidence for cytotoxic potency. Int Immunol 2000, 12:585-596.
13. Admyre C., Johansson S.M., Qazi K.R., Filen J.J., Lahesmaa R., Norman M., et al. Exosomes with immune modulatory features are present in human breast milk. J Immunol 2007, 179:1969-1978.
14. Mincheva-Nilsson L., Baranov V. The role of placental exosomes in reproduction. Am J Reprod Immunol 2010, 63:520-533.
15. Faure J., Lachenal G., Court M., Hirrlinger J., Chatellard-Causse C., Blot B., et al. Exosomes are released by cultured cortical neurons. Mol Cell Neurosci 2006, 66:4795-4801.
16. Andre F., Schartz N.E., Movassagh M., Flament C., Pautier P., Morice P., et al. Malignant effusions and immunogenic tumor-derived exosomes. Lancet 2002, 360:295-305.
17. Hedlund M., Nagaeva O., Kargl D., Baranov V., Mincheva-Nilsson L. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS ONE 2011, 6:e16899.
18. Lespagnol A., Duflaut D., Beekman C., Blanc L., Fiucci G., Marine J.C., et al. Exosome secretion including the DNA damage-induced p53-dependent secretory pathway, is severily compromized in TSAP/Steap3-null mice. Cell Death Diff 2008, 15:1723-1733.
19. Van Niel G., Porto-Carreiro I., Simoes S., Raposo G. Exosomes: a common pathway for a specialized function. J Biochem 2006, 140:13-21.
20. Yu X., Harris S.L., Levine A.J. The regulation of exosome secretion: a nover function of the P53 protein. Cancer Res 2006, 66:4795-4801.
21. Wolfers J., Lozier A., Raposo G., Regnault A., Thery C., Masurier C., et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001, 3:297-303.
22. Dai S., Wan T., Wang B., Zhou X., Xiu F., Chen T., et al. More efficient induction of HLA-A*0201-restricted and carcinoembryonic (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin Cancer Res 2005, 11:7554-7563.
23. Clayton A., Mitchell J.P., Court J., Masson M.D., Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte response to interleukin-2. Cancer Res 2007, 67:7458-7466.
24. Runz S., Keller S., Rupp C., Stoeck A., Issa Y., Koensgen D., et al. Malignant ascites derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol 2007, 107:563-571.
25. Mincheva-Nilsson L., Nagaeva O., Chen T., Stendahl U., Antsiferova J., Mogren I., et al. Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival. J Immunol 2006, 176:3585-3592.
26. Hedlund M., Stenqvist A-C., Nagaeva O., Kjellberg L., Wulff M., Baranov V., et al. Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol 2009, 183:340-351.
27. Chen W., Wang J., Shao C., Liu S., Yu Y., Wang Q., et al. Efficient induction of antitutmor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol 2006, 36:1598-1607.
28. Cho J.A., Lee Y.S., Kim S.H., Ko J.K., Kim C.W. MHC-independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models. Cancer Lett 2009, 275:256-265.
29. André F., Chaput N., Schratz N.E., Flament C., Aubert N., Bernard J., et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functiona MHC class I/peptide complexes to dendritic cells. J Immunol 2004, 172:2126-2136.
30. Chaput N., Scharts N.E., André F., Taieb J., Novault S., Bonnaventure P., et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naïve Tc1 lymphocytes leading to tumor rejection. J Immunol 2004, 172:2137-2146.
31. Navabi H., Croston D., Hobot J., Clayton A., Zitvogel L., Jasani B., et al. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol Dis 2005, 35:149-152.
32. Dai S., Wei D., Wu Z., Zhou X., Wei X., Huang H., et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 2008, 16:782-790.
33. Andreola G., Rivoltini L., Castelli C., Huber V., Perego P., Deho P., et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002, 195:13031316.
34. Huber V., Fais S., Iero M., Lugini L., Canese P., Squarcina P., et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005, 128:1796-1804.
35. Wada J., Onishi H., Suzuki H., Yamasaki A., Nagai S., Morisaki T., et al. Surface bound TGF-beta1 on effusion-derived exosomes participates in maintenance of number and suppressive function of T regulatory cells in malignant effusions. Anticancer Res 2010, 30:3747-3757.
36. Clayton A., Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cell Moll Dis 2005, 34:206-213.
37. Clayton A., Mitchel J.P., Court J., Linnane S., Mason M.D., Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008, 180:7249-7258.
38. Liu C., Yu S., Zinn KWang J., Zhang L., Jia Y., Lappes J.C., et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 2006, 176:1375-1385.
39. Iero M., Valenti R., Huber V., Filipazzi P., Parmiani G., Fais S., et al. Tumor-released exosomes and their implications in cancer immunity. Cell Death Diff 2008, 8:0-8. 8.
40. Costello R.T., Fauriat C., Sivori S., Marcenaro E., Olive D. Nk cells: innate immunity against hematological malignancies. Trends Immunol 2004, 25:328-333.
41. Kärre K. Natural killer cell recognition of missing self. Nat Immunol 2008, 9:277-480.
42. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003, 3:781-790.
43. Chan C.W., Crafton E., Fan H.N., Flook J., Yoshimura K., Skarica M., et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006, 12:207-213.
44. Groh V., Bruhl A., El-Gabalawy H., Neldon J.L., Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 2003, 100:9452-9457.
45. Jamiesson A.M., Diefenbach A., McMahon C.W., Xiong N., Carlyle J.R., Roulet D.H. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002, 17:19-29.
46. Snyder M.R., Weyand C.M., Goronzy J.J. The double life of NK receptors: stimulation or co-stimulation?. Trends Immunol 2004, 25:25-32.
47. Maasho K., Opoku-Anane J., Marusina A.I., Coligan J.E., Borrego F. NKG2D is a costimulatory receptor for human naïve CD8+ T cells. J Immunol 2005, 174:4480-4484.
48. Burgess S.J., Marusina A.I., Pathmanathan I., Borrego F., Coligan J.E. IL-21 downregulates NKG2D/DAP10 expression on human NK and CD8+ cells. J Immunol 2006, 176:1490-1497.
49. Castriconi R., Cantoni C., Della Chiesa M., Vitale M., Marcenaro E., Conte R., et al. Transforming grouth factor beta 1 inhibits expression of NKP30 and NKG2D receptors: consequenses for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 2003, 100:4120-4125.
50. Smyth M.J., Swann J., Cretney E., Zerafa N., Yokoyama W.M., Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med 2005, 202:583-588.
51. Carlsten M., Björkström N.K., Norell H., Bryceson Y., van Hall T., Baumann B.C., et al. DNAX assesory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 2007, 67:1317-1325.
52. Barham S., Bresnahan M., Geraghty D.E., Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994, 91:6259-6263.
53. Cosman D., Mullberg J., Sutherland C.L., Chin W., Armitage R., Fanslow W., et al. ULBPs, novel MHC class-I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001, 14:123-133.
54. Raulet D.H., Gasser S., Gowen B.G., Deng W., Jung H. Regulation of ligands for the NKG2D activating receptor. Ann Rev Immunol 2013, 31:413-441.
55. Pende D., Rivera P., Marcenaro S., Chang C.C., Biassoni R., Conte R., et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histiotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002, 62:6178-6186.
56. Nausch N., Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008, 27:5944-5958.
57. Gasser S., Orsulic S., Brown E.J., Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
58. Guerra N., Tan Y.X., Jincker N.T., Choy A., Gallardo F., Xiong N., et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008, 28:571-580.
59. O'Callaghan C.A., Cerwenka A., Willcox B.E., Lanier L.L., Bjorkman P.J. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. Immunity 2001, 15:2012011.
60. Strong R.K., MacFarland B.J. NKG2D and related immunoreceptors. Adv Protein Chem 2004, 68:281-312.
61. Fernandez-Messina L., Ashiru O., Boutet P., Aguerra-Gonzales S., Skepper J.N., Reyburn H.T., et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-amchored NKG2D ligands. J Biol Chem 2010, 285:8543-8555.
62. Aguera-Gonzalez S., Boutet P., Peyburn H.T., Vales-Gomez M. Brief residence at the plasma membrane of the MHC class I. related chain B is due to clathrin-mediated cholesterol-dependent endocytosis and shedding. J Immunol 2009, 182:4800-4808.
63. Ashiru O., Botet P., Fernandez-Messina L., Aguera-Gonzalea S., Skepper J.N., Vales-Gomes M., et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells on exosomes. Cancer Res 2010, 70:481-489.
64. Viaud S., Terme M., Flament C., Taieb J., Andre F., Novault S., et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15 Ra. PLoS ONE 2009, 4:e4942.
65. Fernandes-Messina L., Reyburn H.T., Vales-Gomez M. Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Frontiers Immunol 2012, 10.3389/fimmu. 2012.00299.
66. Salih H.R., Holdenrieder S., Steinle A. Soluble NKG2D ligands; prevalence, release and functional impact. Front Biosci 2008, 13:3448-4356.